PTAB invalidates Johnson & Johnson cancer drug patent

The Patent Trial and Appeal Board (PTAB) has invalidated a Johnson & Johnson (J&J) patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

16 May 2019 The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft

11 February 2021 A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.